Dynamic evolution of ponatinib‐resistant mutations in BCR–ABL1‐positive leukaemias revealed by next‐generation sequencing.

Dynamic evolution of ponatinib-resistant mutations in BCR-ABL1-positive leukaemias revealed by next-generation sequencing Keywords: BCR-ABL1; tyrosine kinase inhibitors; next-generation sequencing; drug-resistant mutation; compound mutations EN BCR-ABL1 tyrosine kinase inhibitors next-generation sequencing drug-resistant mutation compound mutations e113 e116 4 12/07/20 20201201 NES 201201 Tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 oncoprotein revolutionized the therapy of leukaemias carrying this fusion. The black line represents the BCR-ABL1 transcript level (%). gl Case 2 (Fig 1B) was a seven-year-old boy with a diagnosis of BCR-ABL1-positive B-ALL. With the increase of CML patients who underwent long-term TKI therapy and the increasing application of TKIs in BCR-ABL1-positive B-ALL, as well as the extensive use of sequential TKIs, the dynamics of resistant clones has become more complicated. [Extracted from the article]